About SymBio Pharmaceuticals
SymBio Pharmaceuticals is a publicly listed company based in Minato (Japan) founded in 2005. Oncology drugs are in-licensed, developed, and commercialized for Asian markets. It operates on a HealthTech model. SymBio Pharmaceuticals has raised $24 million across 1 funding round from investors including Cephalon. The company has 108 employees. Its website symbiopharma.com draws about 10 thousand monthly visits. SymBio Pharmaceuticals offers products and services including SyB V-1901 and SyB L-1701/L-1702. Its focus areas include Pharmaceuticals and Drug Development. Its legal entity is SymBio Pharmaceuticals Limited.
Company details
SymBio Pharmaceuticals is focused on the development of new and innovative drugs to address unmet medical needs. The company operates within the healthcare sector, emphasizing drug development through unique business models and global operations. Collaboration with academia and a strong pipeline of products like SyB V-1901 and SyB L-1701L-1702 are maintained. Efforts are directed towards delivering effective solutions to patients and healthcare professionals in Japan and beyond.
- Headquarters Minato, Japan
- Employees 108
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website symbiopharma.com
- Legal Name Symbio Pharmaceuticals Limited
- Annual Revenue$8.36 M (USD)-46.69as on Dec 31, 2025
- Net Profit-$30.51 M (USD)-24.59as on Dec 31, 2025
- EBITDA-$28.34 M (USD)-14.54as on Dec 31, 2025
- Total Equity Funding$24M (USD)
in 1 rounds
- Latest Funding Round$24M (USD), Series B
Feb 2011
- Investors
- Employee Count108
Products & Services of SymBio Pharmaceuticals
SymBio Pharmaceuticals offers a comprehensive portfolio of products and services, including SyB V-1901 and SyB L-1701/L-1702.
A pharmaceutical product developed for medical treatment purposes.
Pharmaceutical solutions created for specific therapeutic medical needs.
Funding Insights of SymBio Pharmaceuticals
SymBio Pharmaceuticals has successfully raised a total of $24M through 1 strategic funding round. The most recent funding activity was a Series B round of $24 million completed in February 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24M
- Total Rounds 1
- Last Round Series B — $24M
- First Round $24M
(Feb 2011)
- Investors Count 1
All 1 funding rounds of SymBio Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2011 | $24M | Series B | – | – |
1 investors in total: 1 institutional.
Investors in SymBio Pharmaceuticals
SymBio Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Cephalon.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapeutics for central nervous system disorders, pain, and cancer | 1987 | cephalon.com | Frazer, United States |
Investor details for SymBio Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SymBio Pharmaceuticals
1 people are tracked at SymBio Pharmaceuticals (1 in leadership); the tracked headcount is 108.
| Name | Role | Group |
|---|---|---|
Yi Shen | Head Of Strategic Planning And Global Program Management | Leadership |
Complete people profiles for SymBio Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of SymBio Pharmaceuticals
SymBio Pharmaceuticals is a publicly listed company on the TSE with ticker symbol 4582 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jul 2013
- Listed onTSE: 4582
- Listed entitySymbio Pharmaceuticals Limited
- Exchange sectorHealth technology
- ISINJP3383050006
- Share price53.00 JPY (-1.85% on the day) · 2026-10-14
- Market capitalisation4,560,637,253.00 JPY
- EPS (diluted, trailing year)-97.62 JPY
- Volume (last session)413,100
Financials of SymBio Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.31B JPY | -4.78B JPY | -4.44B JPY |
| 2024 | 2.45B JPY | -3.83B JPY | -3.88B JPY |
| 2023 | 5.59B JPY | -1.96B JPY | -715.7M JPY |
| 2022 | 10.01B JPY | 1.18B JPY | 2.06B JPY |
| 2021 | 8.25B JPY | 2.03B JPY | 1.11B JPY |
Detailed financial statements for SymBio Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of SymBio Pharmaceuticals
3 dated milestones of SymBio Pharmaceuticals across 8 years, from founding to its latest funding, stage changes and deals.
- Founded SymBio Pharmaceuticals is founded.
- Funding First funding round of $24.0M.
- IPO Lists on the stock exchange (IPO).
Web traffic of SymBio Pharmaceuticals
The website of SymBio Pharmaceuticals (symbiopharma.com) receives about 10.1K visits a month and ranks #1,553,492 among all websites worldwide, #2,060 in Biotechnology and Pharmaceuticals.
- Monthly visits10.1K
▼ 12.3% vs previous month
- Unique visitors3.7K
per month
- Global rank#1,553,492
among all websites
- Category rank#2,060
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit4.2
- Average visit3 min 46 sec
- DevicesDesktop 57% · Mobile 43%
Websites whose visitors overlap most with SymBio Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| funpep.co.jp | 100% | 26.1K | #1,152,941 | View details | |
| nobelpharma.co.jp | 98% | 14K | #1,697,186 | View details | |
ultmarc.co.jp | ultmarc.co.jp | 89% | #561,905 | – | |
| taisho-holdings.co.jp | 89% | View details | |||
msd.co.jp | msd.co.jp | 89% | #1,046,821 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 29 similar websites and full traffic analytics for SymBio Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 29 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Symbio Pharmaceuticals
Complete news archive for SymBio Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SymBio Pharmaceuticals
SymBio Pharmaceuticals was founded in 2005 and raised its 1st funding round 6 years after it was founded.
SymBio Pharmaceuticals is headquartered in Minato, Japan. It is registered at Minato, Tokyo, Japan.
SymBio Pharmaceuticals is a funded company, having raised a total of $24M across 1 funding round to date. The company's 1st funding round was a Series B of $24M, raised on Feb 2011.
SymBio Pharmaceuticals has 108 employees.
Annual revenue of SymBio Pharmaceuticals is $8.36M as on Dec 31, 2025.
SymBio Pharmaceuticals is focused on the development of new and innovative drugs to address unmet medical needs. The company operates within the healthcare sector, emphasizing drug development through unique business models and global operations. Collaboration with academia and a strong pipeline of products like SyB V-1901 and SyB L-1701L-1702 are maintained. Efforts are directed towards delivering effective solutions to patients and healthcare professionals in Japan and beyond.
SymBio Pharmaceuticals offers SyB V-1901 and SyB L-1701/L-1702.
Yes, SymBio Pharmaceuticals is publicly traded on TSE under the ticker symbol 4582.
SymBio Pharmaceuticals has 1 investor. Key investors include Cephalon.
SymBio Pharmaceuticals operates through Symbio Pharmaceuticals Limited.